Dr. Michael E. Bromberg, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 131
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Temple University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
PA license MD042267L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Temple University Hospital Philadelphia, PA
- Temple Health - Chestnut Hill Hospital Philadelphia, PA
Medical groups
- Temple Faculty Practice Plan Inc (1,368 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 192
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 89 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 20 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 48 |
| Acyclovir Other prescribers in Philadelphia, PA | 45 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 43 |
| Dexamethasone Other prescribers in Philadelphia, PA | 33 |
| Hydroxyurea Other prescribers in Philadelphia, PA | 28 |
| Imatinib Mesylate | 28 |
| Imbruvica (ibrutinib) | 21 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 20 |
| Revlimid (lenalidomide) | 19 |
| Pomalyst (pomalidomide) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $28,831 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.